Regulation Blogs

10|28|20

Election 2020: Issues, Implications, What’s at Stake for Pharma

The presidential election is around the corner, and several key issues are in play, regardless of who wins. From drug pricing to DTC to disparities in healthcare and more, we drill down to what matters for pharma.

08|19|20

Drug Pricing – How Pharma Can Ease the Burden

In this POV, market access gurus Mike Motto, Glen Davis, and Peter Weissberg, discuss recent Trump administration action on drug pricing, the likelihood of further action before the 2020 election, and how pharma manufacturers can provide affordable options for more Americans.

08|10|20

Industry Group Will Create New Standards to Protect Ad Practices and Consumers

As the demand for more privacy protections continues, the ad industry moves to create new standards that protect digital advertising practices, including targeting and messaging, while also maintaining consumer privacy.

03|05|20

CHC to Host 5th Annual Healthcare Policy Conference

The Coalition for Healthcare Communications will host a May 2020 conference on healthcare policy, from the perspective of health marketing & comms pros. Learn more & get the registration link here.

12|30|19

From Price Transparency to Data Privacy: Our Top 10 Blogs of 2019

If you, too, had a busy year and perhaps missed some of what we talked about, here’s a look back at Intouch’s 10 most-read posts of 2019 — read on to get caught up and ready for 2020!

11|25|19

Shoppable Services: Price Transparency Era’s First Real Business Bellwether

Many pharma executive and marketing leaders actively monitor the pricing transparency conversation in search of the meaningful insights that can truly impact their business performance. And while much public attention has been paid to items such as “drug costs in TV commercials” and “CEO testimony before Congress,” little evidence exists that they have actually moved […]

08|29|19

EVP Wendy Blackburn: 5 Options for Managing the DTC Transparency Debacle

Drug pricing is a hot button issue, including the pricing transparency battle, and it’s not going away anytime soon. On July 8, U.S. District Court Judge Amit Mehta ruled that the Department of Health and Human Services had overstepped its authority in requiring pricing disclosures, stating, “That policy very well could be an effective tool […]

07|31|19

Complying With Colorado’s New Drug Price Transparency Law

This POV describes Colorado House Bill 19-1131 and how it could affect pharma marketers. The bill requires that any one-to-one communications between pharmaceutical representatives (or anyone communicating on their behalf) and prescribers must include written information about the wholesale cost of a drug, as well as the names of at least three generic equivalents. The law goes into effect on August 2, 2019.

07|10|19

Federal Judge: Full Stop on Drug Prices in DTC TV Ads

On July 8, U.S. District Court Judge Amit Mehta ruled that the Department of Health and Human Services had overstepped its authority in requiring pricing disclosures. What happens next?

07|02|19

FDA Finalizes Guidance on Mandatory Electronic Submission of Promotional Materials

On Monday, June 24, 2019, the Food and Drug Administration finalized its guidance on electronic submissions of promotional materials. This Intouch POV provides an overview of the most significant aspects of the guidance, including the most important changes from the 2015 draft version.

Load More Posts